MX2016001940A - Antagonistas de v1a para tratar trastornos del sueño por cambio de fase. - Google Patents
Antagonistas de v1a para tratar trastornos del sueño por cambio de fase.Info
- Publication number
- MX2016001940A MX2016001940A MX2016001940A MX2016001940A MX2016001940A MX 2016001940 A MX2016001940 A MX 2016001940A MX 2016001940 A MX2016001940 A MX 2016001940A MX 2016001940 A MX2016001940 A MX 2016001940A MX 2016001940 A MX2016001940 A MX 2016001940A
- Authority
- MX
- Mexico
- Prior art keywords
- phase shift
- sleep disorders
- antagonists
- shift sleep
- relates
- Prior art date
Links
- 230000010363 phase shift Effects 0.000 title abstract 3
- 208000019116 sleep disease Diseases 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 abstract 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dermatology (AREA)
Abstract
Esta invención se refiere a un nuevo uso médico para determinados compuestos químicos y a composiciones que los contienen. La invención se refiere a compuestos que son antagonistas selectivos de V1a para su uso en el tratamiento de trastornos del sueño por cambio de fase, en particular, descompensación horaria. En otro aspecto, la invención se refiere a una composición farmacéutica para su uso en el tratamiento de trastornos del sueño por cambio de fase que comprende un compuesto de acuerdo con la invención y un vehículo farmacéuticamente aceptable.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13180836 | 2013-08-19 | ||
| PCT/EP2014/067264 WO2015024819A1 (en) | 2013-08-19 | 2014-08-12 | V1a antagonists to treat phase shift sleep disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016001940A true MX2016001940A (es) | 2016-06-02 |
Family
ID=48985673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016001940A MX2016001940A (es) | 2013-08-19 | 2014-08-12 | Antagonistas de v1a para tratar trastornos del sueño por cambio de fase. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10265327B2 (es) |
| EP (1) | EP3035939B1 (es) |
| JP (1) | JP6427192B2 (es) |
| KR (1) | KR20160042903A (es) |
| CN (1) | CN105492010B (es) |
| AU (1) | AU2014310733A1 (es) |
| BR (1) | BR112016001948A2 (es) |
| CA (1) | CA2919738A1 (es) |
| CL (1) | CL2016000325A1 (es) |
| CR (1) | CR20160042A (es) |
| EA (1) | EA201690179A1 (es) |
| ES (1) | ES2793929T3 (es) |
| IL (1) | IL243387A0 (es) |
| MA (1) | MA38867A1 (es) |
| MX (1) | MX2016001940A (es) |
| PE (1) | PE20160203A1 (es) |
| PH (1) | PH12016500124A1 (es) |
| PL (1) | PL3035939T3 (es) |
| SG (1) | SG11201600991QA (es) |
| WO (1) | WO2015024819A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ720340A (en) | 2013-12-05 | 2020-03-27 | Hoffmann La Roche | Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crystalline forms thereof |
| WO2017191117A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | V1a receptor antagonists for use in the treatment of renal diseases |
| WO2018133835A1 (en) * | 2017-01-20 | 2018-07-26 | National Institute Of Biological Sciences, Beijing | Nucleoside analogue regulating mammalian circadian rhythm |
| EP3720424B1 (en) | 2017-12-08 | 2022-09-21 | F. Hoffmann-La Roche AG | Pharmaceutical formulation |
| JP2023534713A (ja) * | 2020-07-23 | 2023-08-10 | エフ． ホフマン－ラ ロシュ アーゲー | バソプレシン受容体ｖ１ａアンタゴニストとしてのシクロヘキシル置換トリアゾール |
| JP7688692B2 (ja) * | 2020-07-23 | 2025-06-04 | エフ． ホフマン－ラ ロシュ アーゲー | バソプレシン受容体ｖ１ａアンタゴニストとしてのヘテロアリール－メチル置換トリアゾール |
| WO2024197124A2 (en) * | 2023-03-21 | 2024-09-26 | University Of Miami | Arginine vasopressin receptor (avpr) antagonists and methods of using thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2300376T3 (es) * | 2000-10-27 | 2008-06-16 | Ortho-Mcneil Pharmaceutical, Inc. | Nuevas benzimidazol-2-onas sustituidas utilizadas como antagonistas del receptor de la vasopresina y como moduladores del neuropeptido y. |
| US20050107411A1 (en) * | 2001-12-17 | 2005-05-19 | Macneil Douglas J. | Method for treating circadian rhythm disruptions |
| GB0303852D0 (en) * | 2003-02-19 | 2003-03-26 | Pfizer Ltd | Triazole compounds useful in therapy |
| BRPI0514458A (pt) * | 2004-08-25 | 2008-06-10 | Pfizer | triazolbenzodiazepinas e seu uso como antagonistas de vasopressina |
| EP2370441B1 (en) * | 2008-11-28 | 2013-09-11 | F. Hoffmann-La Roche AG | Arylcyclohexylethers of dihydrotetraazabenzoazulenes for use as vasopressin v1a receptor antagonists |
| JPWO2013176220A1 (ja) * | 2012-05-25 | 2016-01-14 | 国立大学法人京都大学 | 概日リズム調整 |
-
2014
- 2014-08-12 MX MX2016001940A patent/MX2016001940A/es unknown
- 2014-08-12 CA CA2919738A patent/CA2919738A1/en active Pending
- 2014-08-12 JP JP2016535416A patent/JP6427192B2/ja active Active
- 2014-08-12 PL PL14750486T patent/PL3035939T3/pl unknown
- 2014-08-12 EA EA201690179A patent/EA201690179A1/ru unknown
- 2014-08-12 SG SG11201600991QA patent/SG11201600991QA/en unknown
- 2014-08-12 PE PE2016000225A patent/PE20160203A1/es not_active Application Discontinuation
- 2014-08-12 ES ES14750486T patent/ES2793929T3/es active Active
- 2014-08-12 WO PCT/EP2014/067264 patent/WO2015024819A1/en not_active Ceased
- 2014-08-12 AU AU2014310733A patent/AU2014310733A1/en not_active Abandoned
- 2014-08-12 KR KR1020167003917A patent/KR20160042903A/ko not_active Withdrawn
- 2014-08-12 CN CN201480045811.1A patent/CN105492010B/zh active Active
- 2014-08-12 EP EP14750486.4A patent/EP3035939B1/en active Active
- 2014-08-12 BR BR112016001948A patent/BR112016001948A2/pt active Search and Examination
-
2015
- 2015-12-28 IL IL243387A patent/IL243387A0/en unknown
-
2016
- 2016-01-19 PH PH12016500124A patent/PH12016500124A1/en unknown
- 2016-01-21 CR CR20160042A patent/CR20160042A/es unknown
- 2016-02-11 CL CL2016000325A patent/CL2016000325A1/es unknown
- 2016-02-23 MA MA38867A patent/MA38867A1/fr unknown
- 2016-03-09 US US15/065,574 patent/US10265327B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016001948A2 (pt) | 2017-08-01 |
| IL243387A0 (en) | 2016-02-29 |
| EA201690179A1 (ru) | 2016-06-30 |
| ES2793929T3 (es) | 2020-11-17 |
| WO2015024819A1 (en) | 2015-02-26 |
| PE20160203A1 (es) | 2016-04-20 |
| KR20160042903A (ko) | 2016-04-20 |
| MA38867A1 (fr) | 2018-01-31 |
| AU2014310733A1 (en) | 2016-02-04 |
| US10265327B2 (en) | 2019-04-23 |
| JP6427192B2 (ja) | 2018-11-21 |
| PH12016500124A1 (en) | 2016-04-25 |
| JP2016528266A (ja) | 2016-09-15 |
| EP3035939A1 (en) | 2016-06-29 |
| CR20160042A (es) | 2016-04-01 |
| CN105492010A (zh) | 2016-04-13 |
| CL2016000325A1 (es) | 2016-09-30 |
| US20180064727A1 (en) | 2018-03-08 |
| PL3035939T3 (pl) | 2020-07-27 |
| CA2919738A1 (en) | 2015-02-26 |
| HK1217171A1 (zh) | 2016-12-30 |
| CN105492010B (zh) | 2020-01-03 |
| EP3035939B1 (en) | 2020-03-25 |
| SG11201600991QA (en) | 2016-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500124A1 (en) | Via antagonists to treat phase shift sleep disorders | |
| PH12015502615B1 (en) | Chemical compounds | |
| MX2015012478A (es) | Metodos y composiciones para inhibicion de proteinas que contienen bromodominio. | |
| MX343135B (es) | Compuestos de tipo fumagilol y métodos de realización y uso de los mismos. | |
| TN2015000278A1 (en) | Autotaxin inhibitors | |
| GEP20207102B (en) | Sulfonamides as modulators of sodium channels | |
| IN2014DN09805A (es) | ||
| MX2013003309A (es) | Compuestos de benzamida sustituidos. | |
| IN2014DN09804A (es) | ||
| MX2015004604A (es) | Antagonistas de los receptores metabotropicos de glutamato 2/3 (mglu2/3) para el tratamiento de los trastornos autistas. | |
| MX2014008705A (es) | Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos. | |
| MX356755B (es) | Compuestos de tipo fumagilol y metodos para su elaboración y uso. | |
| PH12016500356A1 (en) | Nsaid and sigma receptor ligand combinations | |
| PH12017500810A1 (en) | Substituted 2,4 diamino-quinoline as new anticancer agents | |
| PH12014502032A1 (en) | Treatment of brain cancer | |
| MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
| MY179509A (en) | Piperazine derivatives having multimodal activity against pain | |
| PH12016501095A1 (en) | Gabapentinoids and sigma receptor ligands combinations | |
| MX362879B (es) | Usos novedosos. | |
| MX2020009966A (es) | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. | |
| MX2014000963A (es) | Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide. | |
| MX2014003584A (es) | Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides. | |
| GEP201706614B (en) | Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process | |
| GB201115977D0 (en) | Neurodevelopmental disorders | |
| PH12015500282A1 (en) | N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug |